

## Research Article

# Cisplatin Tumor Biodistribution and Efficacy after Intratumoral Injection of a Biodegradable Extended Release Implant

**Ariella Shikanov,<sup>1</sup> Sergey Shikanov,<sup>2</sup> Boris Vaisman,<sup>1</sup> Jacob Golenser,<sup>3</sup> and Abraham J. Domb<sup>1</sup>**

<sup>1</sup> Department of Medicinal Chemistry and Natural Products, School of Pharmacy, The Hebrew University of Jerusalem, 91120 Jerusalem, Israel

<sup>2</sup> Department of Urology, Hadassah Medical Center, 91120 Jerusalem, Israel

<sup>3</sup> Department of Microbiology and Molecular Genetics, The Kuvim Centre for the Study of Infectious and Tropical Diseases, Hadassah Medical School—Faculty of Medicine, The Hebrew University of Jerusalem, 91120 Jerusalem, Israel

Correspondence should be addressed to Abraham J. Domb, avid@ekmd.huji.ac.il

Received 1 September 2010; Revised 26 November 2010; Accepted 11 January 2011

Academic Editor: Elias Jabbour

Copyright © 2011 Ariella Shikanov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Local delivery of chemotherapeutic drugs has long been recognized as a potential method for reaching high drug doses at the target site while minimizing systemic exposure. Cisplatin is one of the most effective chemotherapeutic agents for the treatment of various tumors; however, its systemic toxicity remains the primary dose-limiting factor. Here we report that incorporation of cisplatin into a fatty acid-based polymer carrier followed by a local injection into the solid tumor resulted in a successful tumor growth inhibition in heterotopic mouse bladder tumor model in mice. Platinum concentration in the tumor tissue surrounding the injected implant remained above the therapeutic level up to 14 days after the injection, while the plasma levels were several orders of magnitude lower comparing to systemic delivery. The reported delivery system increased the maximum tolerated dose of cisplatin 5 times compared to systemic delivery, thus potentially improving antitumor efficacy of cisplatin in solid tumor model.

## 1. Introduction

Polymer-based gels are potential carriers that may affect a target tumor while reducing the toxic effects of the loaded drug. Specifically, we suggest that it is possible to optimize their delivery and improve the responsiveness of solid tumors to current chemotherapeutic agents [1].

Cisplatin is widely used for the treatment of testicular, bladder, head and neck, small-cell and non-small-cell lung cancers, but it also possesses substantial side effects, such as nephro-, neuro-, and myelotoxicity [2–4]. Polymer-based cisplatin-loaded drug delivery systems such as liposomes [5], polymeric micelles [6], hydrogels [7], polymeric gels [8], and implants [9] provide an opportunity to deliver high, localized doses of drugs for a prolonged period directly into a tumor or at the site of tumor resection. Implanting

a biodegradable device loaded with antineoplastic agent in the cavity created by the tumor removal provides high local concentration of the drug, killing the surviving malignant cells. This may also prevent the systemic side effects of chemotherapy that is normally associated with intravenous administration. Injectable device may also provide sustained, controlled delivery of the drug to the malignant tumor. In addition, clinicians can perform debulking of large tumor prior to the surgery by exposing the tumor to large concentrations of the drug [10].

Biodegradable polyanhydrides and polyesters are useful materials for controlled drug delivery [11]. In earlier reports we have described the synthesis and various applications of ricinoleic acid-based polyanhydrides as drug carriers [12, 13]. These polymers have hydrophobic backbone with hydrolytically labile anhydride and/or ester that may

hydrolyze to dicarboxylic acids and hydroxy acid monomers when placed in aqueous medium. The toxicity, biodegradation, and elimination of polyanhydrides and aliphatic polyesters have been recently reviewed [14, 15]. The fatty acid components of these polymers undergo extensive metabolism in the body and are mainly excreted in the form of carbon dioxide. The *in vitro* and *in vivo* toxicity tests indicate that these polymers are well tolerated by the tissues and can be generally considered as biocompatible [14]. Furthermore, Vaisman et al. [16] evaluated the safety and biocompatibility of ricinoleic acid-based polymer in rats in high doses intramuscularly, subcutaneously, and intracranially. No systemic tissue damage, polymer-related lesions, or abnormalities could be detected in animals.

Herein we report the application of a biodegradable poly (sebacic-co-ricinoleic acid (P(SA:RA)) polymer for local cisplatin delivery to the solid tumor. Cisplatin can be incorporated by direct mixing with P(SA:RA), which is an injectable fatty acid-based polymer that solidifies in contact with aqueous media [17, 18]. As a result the incorporated drug is released in a sustained manner over a period of days. We hypothesized that cisplatin released from the polymer formulation injected directly in the solid tumor will stop the tumor growth and result in a prolonged survival. Furthermore, we investigated cisplatin local and systemic distribution after single intratumoral injection in heterotopic mouse bladder tumor model.

## 2. Materials and Methods

**2.1. Materials.** Poly (sebacic acid-co-ricinoleic acid ester anhydride) 2:8 and 3:7 were synthesized as previously described [17]. Cisplatin was purchased from AlfaAesar (MA, USA). All solvents were analytical grade from BioLab (Jerusalem, Israel) or Frutarom (Haifa, Israel) and were used without further purification. MBT (mouse bladder tumor) cells were a generous gift from Professor Ofer Gofrit [19] from Hadassah Ein-Karem Hospital (Jerusalem, Israel). Cell culture medium and fetal calf serum (FCS) were obtained from Biological Industries (Beit-Haemek, Israel).

**2.2. Preparation of Formulations and In Vitro Drug Release.** The formulations of P(SA:RA) 2:8 and 3:7 with 5% w/w of cisplatin were prepared under sterile conditions by direct mixing of the polymer with the drug at room temperature. The composition was mixed until a smooth paste was obtained. All formulations were aseptically loaded in syringes and tested for sterility in TSB medium [20]. The obtained formulations were injectable semisolid pastes at room temperature. *In vitro* drug release studies were conducted by injecting 20 mg of the pasty formulations sample in a 50 mL phosphate buffer solution (0.1 M, pH 7.4) at 37°C with constant shaking (100 RPM). The paste hardened to a soft solid shortly after addition to the buffer. The release medium was replaced periodically with fresh buffer solution, and platinum concentration in the solution was determined by Inductively Coupled Plasma Mass Spectrometry (ICP-MS, Perkin Elmer SCIEX). The instrument is based on

Dynamic Reaction Cell technology (ELAN DRC II) with performance-enhancing Axial Field technology. The validity of the analytical procedure was established through a study of specificity, precision, linearity, and accuracy. The linearity of the analytical procedure was evaluated by plotting the detector response (peak area) against analyte concentration. Linear regression analysis was applied to calculate the slope, intercept, and linear correlation coefficient ( $R^2$ ). The limit of detection (LOD) was calculated as signal-to-noise ratio of 3:1, and the limit of the quantification (LOQ) was determined as signal-to-noise ratio of 10:1. The number of points used in each curve was 6. Calibration curves were obtained by programmed injection of different aliquots (10–45  $\mu$ L) of a standard solution with increments of 5  $\mu$ L. The concentration of standard solutions was 10 ppb of platinum in double distilled water, while the linear region was observed at concentration between 0.01 and 100 ppb. All experiments were performed in triplicate.

**2.3. In Vitro Cytotoxicity.** The MBT cells were maintained in monolayer cultures in Dulbecco's modified Eagle's medium containing 10% (v/v) fetal calf serum and supplemented with 200 IU/mL penicillin and 200  $\mu$ L/mL streptomycin (Beit-Haemek, Israel) in 75 cm<sup>2</sup> flasks, in humidified 5% CO<sub>2</sub> in air, incubated at 37°C [21].  $2 \times 10^3$  MBT cells in 100  $\mu$ L of culture medium were seeded in 96-well plates and were incubated for 24 h at 37°C. Cisplatin *in vitro* toxicity was tested by adding serial dilutions of cisplatin in a volume of 10  $\mu$ L to the cultured MBT cells. Cytotoxicity of the polymer degradation products was tested by adding 10  $\mu$ L solution from the blank polymer release study (same sample used as a blank control for the *in vitro* drug release). Cell proliferation was estimated by <sup>3</sup>H-thymidine incorporation [22]. All data presented as mean  $\pm$  STD of triplicate. The data was plotted as a percentage of the data from the control cultures, which were treated identically to the experimental cultures.

**2.4. In Vivo Cisplatin Toxicity.** In a separate study performed to determine maximal tolerated dose (MTD) for the cisplatin-polymer, mice were injected with increasing doses of cisplatin incorporated in the polymer. The dose of 25 mg/kg was chosen as the treatment dose since it was the maximal cisplatin dose at which mice did not show weight loss throughout the study. The dose of 50 mg/kg was determined as (MTD) for cisplatin-polymer formulation, because all mice survived but showed weight loss. The MTD for intraperitoneal delivery was 5 mg/kg, while LD50 for cisplatin in C3H mice is 10 mg/kg [6].

The experiments in mice were approved by the Ethical Committee for Animal Experimentation of the Hebrew University (NIH approval no. OPRR A01-5011).

### 2.5. In Vivo Antitumor Activity

**2.5.1. Inoculation of MBT Cells.** Inbred 8–10-week old female C3H mice, weighing about 20 g (Harlan Laboratories, Israel) were kept under specific pathogen-free (SPF) conditions and given free access to irradiated food and acidified water






FIGURE 1: *In vitro* cumulative release of Pt from P(SA:RA)2:8 (triangles, dashed line) and P(SA:RA)3:7 (stars, solid line) loaded with 5% w/w cisplatin. Each point represents the mean value  $\pm$  STD ( $n = 3$ ). Release was conducted in 0.1 M phosphate buffer, pH 7.4, at 37°C. Pt concentrations were determined by ICP-MS.




FIGURE 2: *In vitro* inhibition effect of cisplatin on MBT cells. Cisplatin at increasing concentrations was added 24 hours after cell incubation in wells.

tumor cells inoculation when the tumor volume exceeded 3.5 cm<sup>3</sup>. However, the growth rate of the tumor was slower in mice injected with the blank polymer that caused statistically significant ( $P < .005$ , ANOVA) delay in tumor progression (Figure 3). The injection of blank polymer into the tumor damaged its structure and delayed its development, but since there was no therapeutic effect on the tumor cells, as was confirmed in *in vitro* cultured cells, the tumor recovered from the physical injury and continued to grow. The injected dose of cisplatin was the same in intratumoral (IT) and intraperitoneal (IP) injection of cisplatin solution (0.1% w/v in saline, 0.1 mL injection, 5 mg/kg); however, IP delivered drug-inhibited tumor growth more efficiently comparing to IT application of solution. After IT injection of cisplatin solution tumors reached the volume of 3 cm<sup>3</sup> 13 days after treatment while after IP treatment only after 16 days. Thus, soluble cisplatin delivered in solution either IT or IP showed efficiency compared to nontreatment and blank polymer groups in prolonging mice life. In the cisplatin/polymer group, mice were injected intratumorally with 50  $\mu$ L of the 1% cisplatin formulation 10 days posttumor inoculation. In 8 mice out of 10 the tumors completely disappeared during the first 10 days after treatment, and mice remained




FIGURE 3: Effect of cisplatin on MBT tumor growth in s.c. implanted mice ( $n = 10$ ). Cisplatin 1% w/w in polymer, 50  $\mu$ L (\*: solid line); blank polymer (■, dashed line); cisplatin solution (0.1% w/v in saline, 100  $\mu$ L injection, 5 mg/kg) ( $\Delta$ , dashed line) were injected intratumorally. No treatment group is designated as ( $\blacklozenge$ ) with solid line, and the group treated IP with cisplatin solution (1% w/v in saline, 100  $\mu$ L injection, 5 mg/kg) is designated as ( $\blacksquare$ ) with solid line. The tumor volume is expressed as mean  $\pm$  STD. Statistically significant differences between the groups are signed with a star ( $P < .05$ , \*).

tumorless till the end of the study (40 days posttumor cells inoculation), while, in the other two mice in this treatment group twenty days posttreatment administration, regrowth of a small nodule at the edge of the original tumor appeared, but its dimensions did not increase above 0.3 cm<sup>3</sup> till the end of the study (40 days posttumor cells inoculation).

**3.4. Platinum Tumor Distribution.** In this study we measured total platinum levels rather than intact cisplatin. Cisplatin is not stable in biological fluids and undergoes ligand-exchange reaction that result in metabolites with different biological activity. Although determining concentrations of both intact cisplatin and its various metabolites would be a more accurate way to predict its activity, measuring total serum platinum is traditionally used for clinical pharmacokinetics assays [8].

Platinum content in the tumor mass gradually decreased over the time course of 14 days (Figure 4), while 90% of the injected platinum was found in the tumor tissue 24 hours after the injection decreasing to 12% of the injected platinum at 14 days.

The peak platinum concentrations ( $C_{max}$ ) in tumor tissue at different time points were defined as the amount of platinum per milligram tumor tissue excluding non-degraded formulation (Figure 5). In the first day after injection, platinum concentration in the tumor tissue was still low, which corresponded with the *in vitro* release results. However, three days after the intratumoral injection, platinum concentration was the greatest and reached 8.8  $\mu$ g/mg, while platinum concentration in plasma was only 0.12  $\mu$ g/ml.  $C_{max}$  gradually decreased in the following days, and 14 days after the injection platinum concentration in tumor was 0.3  $\mu$ g/mg that is still high enough to induce cytotoxic




FIGURE 4: The time profile of platinum remaining in the tumor after intratumoral injection of cisplatin/polymer formulation (1% w/w, 50  $\mu$ L). Values are expressed as mean  $\pm$  STD ( $n = 6$ ).




FIGURE 5: The time profile of platinum maximal concentration ( $C_{max}$ ) in the tumor tissue after intratumoral injection of cisplatin/polymer formulation (1% w/w, 50  $\mu$ L). Values are expressed as mean ( $n = 6$ ).

effect [23]. For comparison, systemic injection of 10 mg/kg free cisplatin produced tumor platinum concentration of 0.014  $\mu$ g/mg [24], which is lower than  $C_{max}$  14 days after intratumoral injection of cisplatin/polymer formulation.

The cisplatin/polymer formulation was injected into the center of the tumor; therefore, platinum distribution is expected to be radial, while the greater concentrations are found at the injection site with gradual decrease toward the tumor boarder. Each line in Figure 6 represents platinum concentration pattern at one time point from the center of the tumor toward the edge over the distance in millimeters. After 24 hours subsequent to injection, the maximal platinum concentration of 1.1  $\mu$ g/mg tumor tissue was found close to the injection site, and it decreased gradually to 0.01  $\mu$ g/mg at a distance of 4.4 mm from the injection site that is still considered above the therapeutic level. The greatest platinum tumor tissue concentration was found at 3 and 4 days after the injection, reaching 8.8  $\mu$ g/mg and 3.8  $\mu$ g/mg, respectively. After 14 days, platinum levels at the injection sites were still above the therapeutic level. Interestingly, in the first 4 days after the treatment, greater gradient was observed between the injection site and the distant areas of the tumor. However, at the later period, the platinum content in the tumor tissue was more equally




FIGURE 6: Cisplatin tumor tissue distribution after intratumoral injection of cisplatin/polymer formulation (1% w/w, 50  $\mu$ L). Each curve represents a different time point when the mice were sacrificed and their tumors processed. Values are expressed as mean ( $n = 6$ ).




FIGURE 7: Platinum (Pt) levels in plasma. Pt levels in mice plasma were determined by ICP-MS. Each data point represents the average of six mice  $\pm$  STD.

distributed that can be explained by the drug diffusion and the clearance from the injection site.

**3.5. Platinum Plasma Levels.** As reported elsewhere [6], the plasma platinum levels after IV administration of free cisplatin were 11.7  $\mu$ g/mL at time zero and decreased during the following 12 hours to 1  $\mu$ g/ml. After intratumoral injection of cisplatin/polymer formulation platinum plasma levels gradually increased from less than 0.1  $\mu$ g/mL after 24 hours and peaked at 0.15  $\mu$ g/mL on days 4–6, followed by sharp decrease to 0.06  $\mu$ g/mL on day 8 (Figure 7). The platinum plasma levels are closely related to the events occurring in the tumor, where the polymer releases the incorporated drug. Importantly, platinum plasma levels after intratumoral polymer injection were several orders of magnitude lower comparing to systemic delivery at all time points.

**3.6. Macroscopic and Histopathological Evaluation.** Figure 8 shows the macroscopic view of the tumors dissected from mice and sectioned in cryostat. Figure 8(a) shows the MBT




FIGURE 8: Macroscopic view of frozen tumor tissues at cryostat sectioning: (a) tumor treated with cisplatin/polymer formulation and excised 3 days after injection; (b) tumor treated with cisplatin/polymer formulation and excised 7 days after injection; (c) tumor treated with the blank polymer and excised 3 days after injection; (d) untreated tumor. The polymeric formulation is assigned with the star (\*), the necrotic tissue with the white circle (○), the infiltration of the inflammation cells with a black circle (●), and the intact tumor cells with a black rhomb (♦).

tumor treated with 50  $\mu$ L of 1% w/w cisplatin/polymer formulation and removed 3 days after treatment. The formulation's color is yellow because of the cisplatin color and can be easily recognized (designated as (\*), and contoured with white line). Three days after formulation injection, large portion of the injected formulation was still found in the center of the tumor tissue, and the formulation did not totally degrade. A region of a reddish tissue surrounded the injected formulation, which was histologically proven to be a necrotic/inflammatory process (designated as (○) and contoured with green line), followed by the intact tumor cells (designated as (♦)), as was proved in the histopathological evaluation of the tissue. Seven days after the formulation injection, 20% of platinum was still found in the tumor tissue, but the formulation has already degraded, and the injection site remained free of the polymer and tumor cells

(Figure 8(b)). Around the injection site, the necrotic region increased in size, which applies to continuous cytotoxic activity (designated as (○) and contoured with green line), followed by the intact tumor cells (designated as (♦)). Blank polymer was injected into the tumors and sectioned similarly to eliminate the possibility of the blank polymer cytotoxic activity. Figure 8(c) shows the tumor with the blank polymer 3 days after injection. The polymer region is surrounded by a mild inflammation region followed by tumor cells, and while partial effect of the polymer on the tumor cells cannot be excluded it was less vigorous than with cisplatin. For comparison, Figure 8(d) shows the tumor without treatment.

The changes appearing in the tumor tissue at the formulation injection site and in more distant regions are shown in the panoramic view of the histology images of the tumors injected with cisplatin/polymer formulation (Figure 9(a)).




FIGURE 9: Histology of the MBT tumor injected intratumorally with cisplatin/polymer formulation (1% w/w, 50  $\mu$ L). (a) Magnification  $\times 10$ , panoramic view of the slice; (b) magnification  $\times 40$ , enlargement of the cisplatin/polymer region and the surrounding necrotic area; (c) magnification  $\times 40$ , enlargement of the border between the end of the necrotic area and start of the intact tumor area; (d) magnification  $\times 40$ , enlargement of the intact tumor area beyond the effect of cisplatin. The polymeric formulation is assigned with the star (\*), the necrotic tissue with the white circle ( $\circ$ ), the infiltration of the inflammation cells with a black circle ( $\bullet$ ), and the intact tumor cells with a black rhomb ( $\blacklozenge$ ).




FIGURE 10: Histology of nontreated MBT tumor (magnification  $\times 40$ ), intact tumor cells.

Only necrotic cells are present at the formulation-tumor interface (higher magnification, Figure 9(b)). Along with the necrosis progression, inflammation process is evident, and the region of dead tumor cells extends up to 3.5 mm from the cisplatin formulation. Figure 9(c) is a higher magnification of a border region between the necrotic process and the unaffected intact tumor tissue, followed by mainly tumor cells (Figure 9(d)). The region in the tumor where cisplatin did not diffuse and was below therapeutic dose (Figure 9(d)) has similar cells appearance as in the nontreated tumor




FIGURE 11: Histology of the MBT tumor injected intratumorally with blank polymer. (a) Magnification  $\times 20$ ; (b) magnification  $\times 40$ , enlargement of the blank polymer and the surrounding mild inflammation area; bar: 0.1 mm; the polymeric formulation is assigned with the star (\*), the necrotic tissue with the white circle ( $\circ$ ), the infiltration of the inflammation cells with a black circle ( $\bullet$ ), and the intact tumor cells with a black rhomb ( $\blacklozenge$ ).

(Figure 10). Importantly, tumor cells density became noticeably lower in both necrotic regions and the region beyond the border, which results in enhanced drug penetration and the cytotoxic effect [25]. Figure 11 shows the appearance of the MBT tumor without treatment; no necrosis or inflammation process was evident in the tumor tissue.

Efficacy studies showed that intratumoral injection of a blank polymer caused a delay in tumor growth (Figure 3). Histological evaluation of the tumors injected with the blank polymer revealed a mild inflammatory reaction and no infiltration region around the polymer for 0.3 mm. Beyond the 0.3 mm, intact tumor cells appear again, as shown in Figures 11(a) and 11(b).

#### 4. Discussion

The toxicity of conventional systemic cancer chemotherapy has severely limited the safety and effectiveness of such therapy, and its impact on the quality of life of patients hampers

its wider clinical application [8]. Plasma concentrations are often used as a marker of cytotoxic exposure; however, drug delivery to the tumor is determined not only by plasma concentrations but also by distribution from plasma into the extracellular fluid (ECF) of the tumor and from the ECF into the cells. Solid tumors have several potential barriers to drug delivery that may limit drug penetration, such as alteration of distribution of blood vessels, blood flow, interstitial pressure, and microcirculation in the tumor [23]. Therefore, high systemic levels of the cytotoxic drug often cause systemic toxicity without reaching effective concentrations in the tumor.

Various injectable drug delivery systems have been investigated for local delivery of cisplatin and other anticancer agents. Intradosed, a collagen gel, loaded with cisplatin and epinephrine, has been shown to be effective for the treatment of head and neck and hepatocellular cancers [26]. Intradosed is an injectable gel that releases cisplatin after intratumoral injection. However, the semiliquid phase of the collagen gel released its content in short time period of hours till couple of days that evokes a need for repeated administrations. Another injectable biodegradable PEG, PLGA polymer system for intratumoral chemotherapy, is Atrigel. This system has a similar drug release period; however, the solidification mechanism involves solvent displacement that can result in higher systemic toxicity. Interestingly, platinum serum levels in rats were 10 times higher after Atrigel injection [8] comparing to the mice serum levels reported in this study, hence presenting lower systemic toxicity of the described formulation combined with local efficiency against tumor cells.

Poly (sebacic co-ricinoleic acid) 2 : 8 used in this study is a hydrophobic polymer, built of natural fatty acids, which can be used for the release of hydrophobic or hydrophilic drugs. The polymeric paste formulation with cisplatin is injectable through a 23-gauge needle and it forms a gel in contact with body fluids by a mechanism that does not involve solvent leaching or temperature change [17, 18]. The purpose of this study was to evaluate the effect of cisplatin-polymer formulation injected intratumorally in heterotopic model in mice compared to immediate release formulation after IP and IT delivery. Interestingly, we noticed that IP cisplatin delivery delayed tumor growth more efficiently compared to the same solution delivered IT. A possible explanation of the superior efficiency in tumor treatment of IP delivery is that the drug was delivered through the blood supply to the tumor and had better chances reaching all the tumor regions, while in the direct injection of cisplatin solution to the tumor the delivery is limited to the injection site, and cisplatin penetration can be inhibited by intratumoral interstitial pressure [27]. Moreover, cisplatin in solution is cleared almost immediately leaving other regions of the tumor untreated. In contrast to IP or IT delivery of cisplatin solution, the described polymeric formulation formed a semisolid implant *in situ* as was confirmed after tumor excision and sectioning [18]. Because of the hydrophobic nature of the polymer, there was no burst effect upon the formulation injection, and the drug was released at controlled rate, as was determined by plasma platinum

levels monitoring. The levels of platinum in the tumors treated with cisplatin/polymer formulation were above the therapeutic threshold during two weeks after the injection, without any signs of systemic toxicity. Importantly, incorporation of cisplatin in the polymer that delivered the drug over prolonged period of time allowed increasing MTD 5 times compared to immediate release formulation, hence injecting 25 mg/kg in polymer versus only 5 mg/kg in solution. Thus, the effectiveness of the polymeric formulation in treating MBT tumor in the described heterotopic model can be the result of higher dose, slow prolonged release and exposure to the drug, and greater surface area of contact between the tumor and the formulation.

Cisplatin is not stable in biological fluids and undergoes ligand-exchange reaction that results in aquated cisplatin that gradually is transformed to other metabolites through reaction with glutathione, albumin, and nucleotides. Although both intact cisplatin and its metabolites are biologically active, it is the intact cisplatin that is responsible for nephrotoxicity. Thus, it can be assumed that systemic platinum levels found after local delivery of cisplatin in the polymer formulation are mainly in the form of biological metabolites, rather than unmodified cisplatin, because of the longer time cisplatin is exposed to biological fluids [24, 28].

Moreover, P(SA : RA) has been shown to be effective in treating solid tumors with paclitaxel, which is highly potent hydrophobic chemotherapeutic drug [29, 30]. P (SA : RA)-based polymeric system is unique because it can serve as a vehicle for delivery of both hydrophilic and hydrophobic drugs concomitantly in a single injection, thus increasing the therapeutic potential of the formulation [31–33].

## 5. Conclusion

The results of this work indicate that treatment with the polymer formulation of cisplatin had a positive outcome and inhibited the growth of the tumors. Distribution studies of cisplatin after intratumoral injection showed high and effective concentrations in the tumors. Histological studies proved the existence of the necrotic process caused by the cytotoxic drug.

## References

- [1] K. A. Walter, R. J. Tamargo, A. Olivi et al., "Intratumoral chemotherapy," *Neurosurgery*, vol. 37, no. 6, pp. 1129–1145, 1995.
- [2] D. H. Moore, "Chemotherapy for recurrent cervical carcinoma," *Current Opinion in Oncology*, vol. 18, no. 5, pp. 516–519, 2006.
- [3] C. A. Rabik and M. E. Dolan, "Molecular mechanisms of resistance and toxicity associated with platinating agents," *Cancer Treatment Reviews*, vol. 33, no. 1, pp. 9–23, 2007.
- [4] C. N. Sternberg, S. M. Donat, J. Bellmunt et al., "Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer," *Urology*, vol. 69, no. 1, pp. 62–79, 2007.

- [5] S. Ramachandran, A. P. Quist, S. Kumar, and R. Lal, "Cisplatin nanoliposomes for cancer therapy: AFM and fluorescence imaging of cisplatin encapsulation, stability, cellular uptake, and toxicity," *Langmuir*, vol. 22, no. 19, pp. 8156–8162, 2006.
- [6] H. Uchino, Y. Matsumura, T. Negishi et al., "Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats," *British Journal of Cancer*, vol. 93, no. 6, pp. 678–687, 2005.
- [7] M. Konishi, Y. Tabata, M. Kariya et al., "In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel," *Journal of Controlled Release*, vol. 92, no. 3, pp. 301–313, 2003.
- [8] F. A. Chen, M. A. Kuriakose, M. X. Zhou, M. D. DeLacure, and R. L. Dunn, "Biodegradable polymer-mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model," *Head and Neck*, vol. 25, no. 7, pp. 554–560, 2003.
- [9] D. T. T. Yapp, D. K. Lloyd, J. Zhu, and S. M. Lehnert, "Cisplatin delivery by biodegradable polymer implant is superior to systemic delivery by osmotic pump or i.p. injection in tumor-bearing mice," *Anti-Cancer Drugs*, vol. 9, no. 9, pp. 791–796, 1998.
- [10] S. K. Dordunoo, A. M. C. Oktaba, W. Hunter, W. Min, T. Cruz, and H. M. Burt, "Release of taxol from poly( $\epsilon$ -caprolactone) pastes: effect of water-soluble additives," *Journal of Controlled Release*, vol. 44, no. 1, pp. 87–94, 1997.
- [11] R. Langer, "Biomaterials in drug delivery and tissue engineering: one laboratory's experience," *Accounts of Chemical Research*, vol. 33, no. 2, pp. 94–101, 2000.
- [12] D. Teomim and A. J. Domb, "Fatty acid terminated polyanhydrides," *Journal of Polymer Science, Part A: Polymer Chemistry*, vol. 37, no. 16, pp. 3337–3344, 1999.
- [13] D. Teomim, A. Nyska, and A. J. Domb, "Ricinoleic acid-based biopolymers," *Journal of Biomedical Materials Research*, vol. 45, no. 3, pp. 258–267, 1999.
- [14] M. Hakkarainen, "Aliphatic polyesters: abiotic and biotic degradation and degradation products," *Advances in Polymer Science*, vol. 157, pp. 113–138, 2002.
- [15] D. S. Katti, S. Lakshmi, R. Langer, and C. T. Laurencin, "Toxicity, biodegradation and elimination of polyanhydrides," *Advanced Drug Delivery Reviews*, vol. 54, no. 7, pp. 933–961, 2002.
- [16] B. Vaisman, M. Motiei, A. Nyska, and A. J. Domb, "Biocompatibility and safety evaluation of a ricinoleic acid-based poly(ester-anhydride) copolymer after implantation in rats," *Journal of Biomedical Materials Research Part A*, vol. 92, no. 2, pp. 419–431, 2010.
- [17] M. Y. Krasko, A. Shikanov, A. Ezra, and A. J. Domb, "Poly(ester anhydride)s prepared by the insertion of ricinoleic acid into poly(sebacic acid)," *Journal of Polymer Science, Part A: Polymer Chemistry*, vol. 41, no. 8, pp. 1059–1069, 2003.
- [18] A. Shikanov and A. Domb, "Poly(sebacic acid-co-ricinoleic acid) biodegradable injectable in situ gelling polymer," *Biomacromolecules*, vol. 7, no. 1, pp. 288–296, 2006.
- [19] M. Elkin, S. Ayes, T. Schneider, N. De Groot, A. Hochberg, and I. Ariel, "The dynamics of the imprinted H19 gene expression in the mouse model of bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine," *Carcinogenesis*, vol. 19, no. 12, pp. 2095–2099, 1998.
- [20] S. Soncin, V. L. Cicero, G. Astori et al., "A practical approach for the validation of sterility, endotoxin and potency testing of bone marrow mononucleated cells used in cardiac regeneration in compliance with good manufacturing practice," *Journal of Translational Medicine*, vol. 7, pp. 1–9, 2009.
- [21] E. S. Y. Chan, A. R. Patel, A. K. Smith et al., "Optimizing Orthotopic Bladder Tumor Implantation in a Syngeneic Mouse Model," *Journal of Urology*, vol. 182, no. 6, pp. 2926–2931, 2009.
- [22] I. Yudovin-Farber, N. Beyth, A. Nyska, E. I. Weiss, J. Golenser, and A. J. Domb, "Surface characterization and biocompatibility of restorative resin containing nanoparticles," *Biomacromolecules*, vol. 9, no. 11, pp. 3044–3050, 2008.
- [23] W. C. Zamboni, A. C. Gervais, M. J. Egorin et al., "Disposition of platinum (Pt) in B16 murine melanoma tumors after administration of cisplatin or pegylated liposomal-cisplatin formulations (SPI-077 and SPI-077B103)," *Clinical Cancer Research*, vol. 6, no. 132, 2000.
- [24] W. C. Zamboni, A. C. Gervais, M. J. Egorin et al., "Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin," *Clinical Cancer Research*, vol. 8, no. 9, pp. 2992–2999, 2002.
- [25] H. J. Kuh, S. H. Jang, M. G. Wientjes, J. R. Weaver, and J. L. S. Au, "Determinants of paclitaxel penetration and accumulation in human solid tumor," *Journal of Pharmacology and Experimental Therapeutics*, vol. 290, no. 2, pp. 871–880, 1999.
- [26] T. J. Vogl, K. Engelmann, M. G. Mack et al., "CT-guided intratumoural administration of cisplatin/epinephrine gel for treatment of malignant liver tumours," *British Journal of Cancer*, vol. 86, no. 4, pp. 524–529, 2002.
- [27] T. P. F. Gade, I. M. Buchanan, M. W. Motley, Y. Mazaheri, W. M. Spees, and J. A. Koutcher, "Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors," *Clinical Cancer Research*, vol. 15, no. 1, pp. 247–255, 2009.
- [28] W. C. Zamboni, A. C. Gervais, M. J. Egorin et al., "Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma," *Cancer Chemotherapy and Pharmacology*, vol. 53, no. 4, pp. 329–336, 2004.
- [29] A. Shikanov, S. Shikanov, B. Vaisman, J. Golenser, and A. J. Domb, "Paclitaxel tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant," *International Journal of Pharmaceutics*, vol. 358, no. 1–2, pp. 114–120, 2008.
- [30] S. Shikanov, A. Shikanov, O. Gofrit, A. Nyska, B. Corn, and A. J. Domb, "Intratumoral delivery of paclitaxel for treatment of orthotopic prostate cancer," *Journal of Pharmaceutical Sciences*, vol. 98, no. 3, pp. 1005–1014, 2009.
- [31] H. Nagai and Y. Sumino, "Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy," *Recent Patents on Anti-Cancer Drug Discovery*, vol. 3, no. 3, pp. 220–226, 2008.
- [32] V. R. Recinos, B. M. Tyler, K. Bekelis et al., "Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model," *Neurosurgery*, vol. 66, no. 3, pp. 530–537, 2010.
- [33] S. I. Sugiyama, Y. Yamashita, T. Kikuchi, Y. Sonoda, T. Kumabe, and T. Tominaga, "Enhanced antitumor effect of combined-modality treatment using convection-enhanced delivery of hydrophilic nitrosourea with irradiation or systemic administration of temozolomide in intracranial brain tumor xenografts," *Neurological Research*, vol. 30, no. 9, pp. 960–967, 2008.



# Hindawi

Submit your manuscripts at  
<http://www.hindawi.com>

